Where Does Cannabinoid Research and Development Actually Stand?
Cannabinoid R&D now splits into two real tracks: FDA botanical drug development using whole-plant extracts, and lab production of minor cannabinoids via synthesis or biosynthesis. Both are maturing fast but neither is close to personalized medicine yet.
Cannabinoid R&D stopped being one thing a while ago. There are now two distinct tracks, and conflating them is how operators waste money.
Botanical drug development is real pharma now
Joel Stanley, founding CEO of Charlotte's Web and now founder of Ozna Biosciences, and Dr. Marcel Bonn-Miller laid out what this actually requires on Cannabis Was Medicine. Now the Proof Is Catching Up. Ozna's lead candidate, AJA-001, targets irritability and aggression in autism spectrum disorder, and it contains over 6,000 compounds that each have to be identified and kept within spec batch after batch. That's the cost of a 2016 FDA botanical drug guidance that finally let whole-plant extracts get approved like conventional drugs. British American Tobacco has put $15 million into the program through a partnership called Deloria, which tells you where serious capital thinks the margin is: not in commoditized flower, but in regulated, reproducible botanical drugs built on a decade of Charlotte's Web's standardized genetics and extraction work.
Bonn-Miller, who said he's been doing cannabinoid research for about 23 years, described the field's shift plainly: funding used to come almost entirely from agencies studying cannabis harms, and now there are dedicated journals, multiple conferences, and accredited university programs. That's not hype, that's infrastructure building under the hype.
Minor cannabinoid manufacturing is a separate, more immediate business
Shane Johnson, SVP and GM of BayMedica, explained on How Minor Cannabinoids are Made why most minor cannabinoids on shelves today, like CBC and THCV, aren't extracted from plants at all. The plant either can't make enough of them alone or can't make them pure. BayMedica uses engineered yeast (biosynthesis) and chemical synthesis instead, and Johnson pointed out this isn't exotic: aspirin, vitamins, and the caffeine in energy drinks are synthesized too. He said price only moves one direction, down, and that CBD isolate fell from roughly $60,000 a kilo to around $300. Real consumer adoption, in his view, kicks in once a cannabinoid's price drops below roughly $3,000 to $5,000 per kilo.
Cameron Clarke of Kanha confirmed the demand side of this on Kanha Edibles on a Thai Beach. Kanha has worked with minor cannabinoids for about eight years, starting with a CBN sleep tincture built on anecdotal evidence before real studies caught up. They now use THCV, CBN, CBG, and CBC across their line, often breeding minors back into high-THC genetics to recreate a full-spectrum effect.
Personalized cannabinoid medicine is not close
Kanha tried DNA-based personalized tinctures with EndoCanna Health and shelved it, Clarke said, because retail shelf space is too expensive for a niche product. Johnson was more direct: true personalized cannabinoid medicine is likely a decade or more away, and it requires isolating pure cannabinoids and studying specific ratios in human subjects with real clinical data, not full-spectrum extracts.
What this means for operators
If you're chasing R&D dollars, know which track you're actually on. Botanical drug development is a pharma play requiring FDA rigor, patient capital, and a single indication you don't drift from. Minor cannabinoid manufacturing is a cost and purity game that rewards whoever gets price down fastest. Personalized medicine is not a product you can launch this year. Pick one lane and build the infrastructure for it.
Related questions
Does synthesizing a cannabinoid make it less effective or less safe?
No. Shane Johnson of BayMedica said a compound is a compound regardless of how it's made, as long as chirality, stereochemistry, and impurity profiles are controlled. Everyday products like aspirin and vitamins are synthesized too.
What's the biggest barrier to studying cannabinoids in medicine?
Decades of Schedule I status made rigorous clinical research difficult in the US and abroad, according to Shane Johnson, which stalled the evidence base needed for medical schools to teach the endocannabinoid system.
Is full-spectrum or single-cannabinoid research the better R&D path?
Both tracks exist and serve different goals. Ozna Biosciences is pursuing full-spectrum botanical drugs through FDA trials, while BayMedica isolates and manufactures single minor cannabinoids like CBC and THCV for consistency and cost control.